Merck & Co. discovers, develops, manufactures, and markets prescription medicines, vaccines, and biologic therapies as a global pharmaceutical company. Its portfolio includes oncology treatments such as Keytruda, vaccines for infectious diseases, and products in cardiovascular, diabetes, and animal health segments through its MSD Animal Health division. The company serves healthcare providers, patients, and governments by supplying innovative therapies and preventive medicines primarily in the United States and international markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 15,529 | — | 5,079 | -3.1% |
| Q2 2025 | 15,806 | — | 4,427 | -24.3% |
| Q3 2025 | 17,276 | — | 5,785 | 45.2% |
| Q4 2025 | 16,400 | — | 2,963 | -31.9% |
| Q1 2026 | 16,286 | 4.9% | -4,240 | -183.5% |
| Q2 2026 | 16,607 | 5.1% | -1,335 | -130.2% |
All markets — KeepWinning global stock screener
Other companies on NYSE: HSBC Holdings plc (HSBC), UnitedHealth Group Incorporated (UNH), GE Aerospace (GE), The Procter & Gamble Company (PG), Morgan Stanley (MS), The Home Depot, Inc. (HD)